Atlas Venture Life Science Advisors, LLC / DAWNGBX
Atlas Venture Life Science Advisors, LLC’s Day One Biopharmaceuticals I Position
Does Atlas Venture Life Science Advisors, LLC own Day One Biopharmaceuticals I (DAWNGBX)? Not currently — the last reported position was 6.41M shares worth $60M in Q4 2025; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$60M
Q4 2025
Shares
6.41M
% of Portfolio
+6.91%
Quarters Held
16
position exited
Position History DAWNGBX
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q4 2025 | 6.41M | $60M | +6.91% |
| Q3 2025 | 6.43M | $45M | +6.02% |
| Q2 2025 | 6.43M | $42M | +6.31% |
| Q1 2025 | 6.43M | $51M | +9.77% |
| Q4 2024 | 6.43M | $81M | +9.94% |
| Q3 2024 | 6.43M | $90M | +8.30% |
| Q2 2024 | 6.43M | $89M | +9.33% |
| Q1 2024 | 6.43M | $106M | +9.80% |
| Q4 2023 | 7.61M | $111M | +13.23% |
| Q3 2023 | 7.61M | $93M | +14.46% |
| Q2 2023 | 7.61M | $91M | +11.31% |
| Q1 2023 | 7.61M | $102M | +13.77% |
| Q4 2022 | 7.57M | $163M | +19.62% |
| Q3 2022 | 8.17M | $164M | +18.06% |
| Q2 2022 | 8.97M | $161M | +26.84% |
| Q1 2022 | 8.20M | $81M | +10.29% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Atlas Venture Life Science Advisors, LLC’s full portfolio or all institutional holders of DAWNGBX.